Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-c

4 hours ago

CagriSema, a combination of cagrilintide and semaglutide, showed significant reduction in HbA1c in adults with type 2 diabetes inadequately controlled by diet and exercise compared to placebo.
The study found significant weight loss with CagriSema: -13.8% with the 2.4 mg dose and -11.8% with the 1.0 mg dose versus -1.4% with placebo.
Adverse events were mostly mild to moderate and gastrointestinal-related, with higher incidence in CagriSema groups (79% for 2.4 mg, 75% for 1.0 mg) versus placebo (66%).
The safety profile of CagriSema was consistent with GLP-1 receptor agonists and previous cagrilintide data, supporting it as a potential novel therapy for early-stage type 2 diabetes.

Hasty Briefsbeta